181 related articles for article (PubMed ID: 15008344)
21. Quercetin Assists Fluconazole to Inhibit Biofilm Formations of Fluconazole-Resistant Candida Albicans in In Vitro and In Vivo Antifungal Managements of Vulvovaginal Candidiasis.
Gao M; Wang H; Zhu L
Cell Physiol Biochem; 2016; 40(3-4):727-742. PubMed ID: 27915337
[TBL] [Abstract][Full Text] [Related]
22. Mrr2 mutations and upregulation are associated with increased fluconazole resistance in Candida albicans isolates from patients with vulvovaginal candidiasis.
Feng W; Yang J; Ji Y; Xi Z; Yang L; Zhu X; Ma Y
Lett Appl Microbiol; 2020 Feb; 70(2):95-101. PubMed ID: 31705810
[TBL] [Abstract][Full Text] [Related]
23. Comparison of the effects of three different anti-fungus drugs on Candida albicans of murine vaginal mucosa.
Chen S; Li S; Liu Z; Wu Y; Tu Y; Li J
J Huazhong Univ Sci Technolog Med Sci; 2007 Apr; 27(2):209-12. PubMed ID: 17497300
[TBL] [Abstract][Full Text] [Related]
24. Comparative resistance of Candida albicans clinical isolates to fluconazole and itraconazole in vitro and in vivo in a murine model.
Valentin A; Le Guennec R; Rodriguez E; Reynes J; Mallie M; Bastide JM
Antimicrob Agents Chemother; 1996 Jun; 40(6):1342-5. PubMed ID: 8725998
[TBL] [Abstract][Full Text] [Related]
25. [Antifungal susceptibility testing of commensal and pathogenic clinical isolates of oral Candida].
Zhao M; Zhou ZT
Shanghai Kou Qiang Yi Xue; 2006 Apr; 15(2):218-20. PubMed ID: 16685371
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of fluconazole and nystatin in the treatment of vaginal Candida species.
Martins HP; da Silva MC; Paiva LC; Svidzinski TI; Consolaro ME
Acta Derm Venereol; 2012 Jan; 92(1):78-82. PubMed ID: 21918792
[TBL] [Abstract][Full Text] [Related]
27. Fluconazole susceptibility of vaginal isolates obtained from women with complicated Candida vaginitis: clinical implications.
Sobel JD; Zervos M; Reed BD; Hooton T; Soper D; Nyirjesy P; Heine MW; Willems J; Panzer H
Antimicrob Agents Chemother; 2003 Jan; 47(1):34-8. PubMed ID: 12499165
[TBL] [Abstract][Full Text] [Related]
28. [25S rDNA genotype and antifungal susceptibility of vaginal Candida albicans].
Zhang X; Liu ZH
Zhonghua Fu Chan Ke Za Zhi; 2016 Apr; 51(4):279-84. PubMed ID: 27116986
[TBL] [Abstract][Full Text] [Related]
29. An Azole-Tolerant Endosomal Trafficking Mutant of Candida albicans Is Susceptible to Azole Treatment in a Mouse Model of Vaginal Candidiasis.
Peters BM; Luna-Tapia A; Tournu H; Rybak JM; Rogers PD; Palmer GE
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28348159
[TBL] [Abstract][Full Text] [Related]
30. The evolution of Candida species and fluconazole susceptibility among oral and vaginal isolates recovered from human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women.
Sobel JD; Ohmit SE; Schuman P; Klein RS; Mayer K; Duerr A; Vazquez JA; Rampalo A;
J Infect Dis; 2001 Jan; 183(2):286-93. PubMed ID: 11204125
[TBL] [Abstract][Full Text] [Related]
31. [Prerequisites for effective therapy of chronic recurrent vaginal candidiasis].
Kunzelmann V; Tietz HJ; Rossner D; Czaika V; Hopp M; Schmalreck A; Sterry W
Mycoses; 1996; 39 Suppl 1():65-72. PubMed ID: 8767274
[TBL] [Abstract][Full Text] [Related]
32. Prevalence of Candida glabrata and its response to boric acid vaginal suppositories in comparison with oral fluconazole in patients with diabetes and vulvovaginal candidiasis.
Ray D; Goswami R; Banerjee U; Dadhwal V; Goswami D; Mandal P; Sreenivas V; Kochupillai N
Diabetes Care; 2007 Feb; 30(2):312-7. PubMed ID: 17259500
[TBL] [Abstract][Full Text] [Related]
33. In vivo activity of terpinen-4-ol, the main bioactive component of Melaleuca alternifolia Cheel (tea tree) oil against azole-susceptible and -resistant human pathogenic Candida species.
Mondello F; De Bernardis F; Girolamo A; Cassone A; Salvatore G
BMC Infect Dis; 2006 Nov; 6():158. PubMed ID: 17083732
[TBL] [Abstract][Full Text] [Related]
34. Vulvovaginal candidiasis in a Flemish patient population.
De Vos MM; Cuenca-Estrella M; Boekhout T; Theelen B; Matthijs N; Bauters T; Nailis H; Dhont MA; Rodriguez-Tudela JL; Nelis HJ
Clin Microbiol Infect; 2005 Dec; 11(12):1005-11. PubMed ID: 16307555
[TBL] [Abstract][Full Text] [Related]
35. [Treatment of recurrent vulvovaginal candidosis with mycosyst (fluconazole)].
Pekhlivanov B; Amaliev I; Ivancheva Kh; Zisova L
Akush Ginekol (Sofiia); 2005; 44 Suppl 2():25-7. PubMed ID: 16028400
[TBL] [Abstract][Full Text] [Related]
36. Reduced fluconazole susceptibility of Candida albicans isolates in women with recurrent vulvovaginal candidiasis: effects of long-term fluconazole therapy.
Shahid Z; Sobel JD
Diagn Microbiol Infect Dis; 2009 Jul; 64(3):354-6. PubMed ID: 19501794
[TBL] [Abstract][Full Text] [Related]
37. Iranian HIV/AIDS patients with oropharyngeal candidiasis: identification, prevalence and antifungal susceptibility of Candida species.
Khedri S; Santos ALS; Roudbary M; Hadighi R; Falahati M; Farahyar S; Khoshmirsafa M; Kalantari S
Lett Appl Microbiol; 2018 Oct; 67(4):392-399. PubMed ID: 30019443
[TBL] [Abstract][Full Text] [Related]
38. A Case Report of Penile Infection Caused by Fluconazole- and Terbinafine-Resistant Candida albicans.
Hu Y; Hu Y; Lu Y; Huang S; Liu K; Han X; Mao Z; Wu Z; Zhou X
Mycopathologia; 2017 Apr; 182(3-4):397-402. PubMed ID: 27659805
[TBL] [Abstract][Full Text] [Related]
39. Clonal spread and azole-resistant mechanisms of non-susceptible Candida albicans isolates from vulvovaginal candidiasis patients in three Shanghai maternity hospitals.
Wu Y; Li C; Wang Z; Gao J; Tang Z; Chen H; Ying C
Med Mycol; 2018 Aug; 56(6):687-694. PubMed ID: 29136186
[TBL] [Abstract][Full Text] [Related]
40. Lack of correlation of 24- vs. 48-h itraconazole minimum inhibitory concentrations with microbiological and survival outcomes in a guinea pig model of disseminated candidiasis.
Odabasi Z; Paetznick VL; Rodriguez JR; Chen E; Rex JH; Leitz GJ; Ostrosky-Zeichner L
Mycoses; 2010 Sep; 53(5):438-42. PubMed ID: 19500259
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
